Episodes (Page 24)
✨
Bioprinting as an innovative tool revolutionizing drug discovery.
Keith Murphy
✨
Merck & Co. enters CD19 bispecific space; gene therapy patient growth.
✨
Learnings from the first batch of Medicare negotiated drug prices.
✨
Discusses new drug candidates highlighted at the European Society of Cardiology.
✨
Thermo Fisher's Meron Mathias discusses ESG compliance in medtech.
Meron Mathias
✨
Amgen's strategy for obesity and diabetes markets.
✨
Haleon drives awareness of public health issues like chronic pain.
Bas Vorsteveld
✨
Dr. Anthony Fritz explains Type 2 diabetes management.
Anthony Fritz
✨
Former Surgeon General Adams on improving clinical trial diversity.
✨
Eli Lilly and Novo Nordisk stock surged in H1 2024.
✨
Pfizer bullish on oral GLP-1; BMS confidence on Eliquis Medicare pricing.
✨
Anticipates potential FDA drug approvals in August.
✨
Discusses Shanghai's biopharma stimulus policies and globalization.
Brian Yang
Dexter Yan
Yaning Wang
✨
Expert Wen-Yu discusses the impact of biologics on COPD treatment.
✨
Dr. Joshua Richter discusses multiple myeloma treatment advancements.
Joshua Richter
✨
Narasimhan's long-term strategy and Merck's RSV contender.
✨
Consumers expect more from health and wellness brands.
Rhea Patten
✨
Discusses the retirement of the US FDA Device Center Director.
Andrew Freeman
Victoria Bradley
✨
Explores latest advancements in heart failure treatment.
✨
Emphasizes early COPD diagnosis for better lung function.
Brittany Little